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Abstract
Studies on the effects of alcohol use on HIV disease progression have been contradictory, with at 
least one study finding a positive effect of low alcohol consumption on CD4 count. In addition, 
most such studies have taken place in the developed West. We investigated the association between 
alcohol use and immune reconstitution through CD4 count response among HIV-infected 
individuals on antiretroviral therapy (ART) at an urban sub-Saharan African clinic. This was a 
retrospective cohort study of treatment-naïve HIV-infected adults initiating ART in Nairobi, Kenya 
and followed for 12 months between January 2009 and December 2012. At enrollment, a 
standardized questionnaire was used to collect data on sociodemographic variables and alcohol 
consumption. CD4 count was measured every six months. Linear regression models assessed the 
association between CD4 count and alcohol consumption, categorized as abstinent, moderate, or 
hazardous. Overall, 854 participants were included, 522 of which were women, with 85 (25.6%) 
men and 50 (9.6%) women reporting any alcohol use, and 8 (2.4%) men and 7 (1.3%) women 
reporting hazardous drinking. At baseline, alcohol use was associated with higher education and 
socioeconomic status. Median CD4 count was higher among alcohol users compared to those who 
abstained at baseline and at 6 and 12 months post-ART initiation, although this was only 
significant at 6 months. There were no differences in adherence between abstainers and drinkers. 
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While overall alcohol use was significantly associated with higher CD4 counts, moderate and 
hazardous use treated separately were not. We conclude that, while alcohol use was associated 
with higher CD4 counts at 12 months post-ART, the mechanism for this association is unclear but 
may reflect unmeasured socioeconomic or nutritional differences. Additional research is required 
on the specific drinking patterns of this population and the types of alcoholic beverages consumed 
to clarify this relationship.
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Introduction
The results of studies on the effect of alcohol use on HIV disease progression are limited and 
contradictory. Several studies have found a correlation between heavy or frequent drinkers 
and lower CD4 counts and higher viral loads (Baum et al., 2010; Samet et al., 2007) 
compared to abstainers, while others have found no correlation (Conen et al., 2013; 
Ghebremichael et al., 2009; Kaslow et al., 1989; Kowalski et al., 2012). In addition, a recent 
French study reported that, compared with abstinent patients, those with low alcohol 
consumption were more likely to have significantly higher CD4 counts, while those 
reporting moderate consumption had CD4 cell counts not significantly different from those 
of abstinent patients (Carrieri et al., 2014). The influence of alcohol consumption on disease 
progression is thought to be mediated by poor adherence to antiretroviral therapy (ART) 
(Braithwaite et al., 2007; Chander, Lau, & Moore, 2006; Cook et al., 2001; Hendershot, 
Stoner, Pantalone, & Simoni, 2009; Jaquet et al., 2010; Samet, Horton, Meli, Freedberg, & 
Palepu, 2004), and delay in seeking care based on a perception that abstinence is required 
for ART initiation (Azar, Springer, Meyer, & Altice, 2010; Braithwaite et al., 2007; Chander 
et al., 2006; Cook et al., 2001; Haberer et al., 2013; Hendershot et al., 2009; Jaquet et al., 
2010; Samet et al., 2004).
While the majority of these studies have been carried out in the developed world, in sub-
Saharan Africa (SSA), which has the highest rate of HIV infection (5.9%) in the world 
(UNAIDS, 2015), patterns of alcohol consumption and even the kinds of alcoholic beverages 
that are present may vary significantly from the Western patterns (Hargreaves et al., 2002; 
Parry et al., 2005; Shaffer, Njeri, Justice, Odero, & Tierney, 2004; Willis, 2002). 
Understanding the role of alcohol on disease progression is crucial in providing appropriate 
screening and treatment regimens, and interventions among these highly at-risk populations.
This study describes the prevalence of alcohol use, explores sociodemographic 
characteristics associated with drinking, and examines the relationship between alcohol 
consumption and CD4 counts among HIV-infected patients at an ART treatment clinic in 
Nairobi, Kenya.
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Methods
This is a retrospective cohort study of HIV-infected adults aged 15 years or older who were 
ART-naïve and initiated ART within 3 months of enrollment in the Coptic Hope Center for 
Infectious Diseases in Nairobi, Kenya between January 2009 and December 2012. The Hope 
Center, established in 2004 in collaboration with the Coptic Orthodox Mission and 
University of Washington (Chung et al., 2009), offers free ART and palliative care to HIV-
infected adults and children, and is supported by the President's Emergency Plan for AIDS 
Relief (PEPFAR) through a cooperative agreement from the US Centers for Disease Control 
and Prevention (CDC).
At clinic enrollment, patients are confirmed as HIV-positive and offered ART if they are 
eligible based on Kenyan national guidelines: WHO stage I or II if CD4 ≤ 350 cells/μl, 
WHO stage III or IV irrespective of CD4 count, and any HIV-infected patient co-infected 
with either Tuberculosis (TB), Hepatitis B with evidence of liver disease, and any patient 
with HIV-associated nephropathy. Patients who report receiving ART prior to enrollment are 
considered ART-experienced; those who report never having received ART are considered 
ART-naïve. Baseline sociodemographic variables and information on alcohol consumption 
are collected using a standardized questionnaire. CD4 counts are regularly obtained at 
enrollment prior to ART initiation, and every 6 months thereafter; samples are processed at 
an on-site laboratory (Becton Dickinson FACSCali-bur, San Jose, CA, USA).
Adherence in this study is measured by treatment interruption using a strategy used earlier 
with similar data (Pyne-Mercier et al., 2011). Clients are required to refill their antiretroviral 
prescriptions every 30 or 60 days, and refills for missed doses are adjusted accordingly at 
each pharmacy visit. If, for example, a client received a 30-day supply on June 1, their next 
scheduled pharmacy refill date would be July 1; treatment interruption would occur if the 
client did not return until July 3 or later. Interruption is measured as the number of late visits 
(3+ days) to the pharmacy to obtain prescription refills.
All patients who initiate ART are seen by a social worker at enrollment who routinely 
inquires about alcohol use. Two questions pertaining to alcohol consumption were used in 
this analysis: “Do you drink alcohol?” (Y/N) and “If yes, number of drinks per week”. 
Alcohol consumption is defined based on National Institute of Alcohol Abuse and 
Alcoholism (NIAAA) criteria and categorized as abstinent, moderate, or hazardous 
(NIAAA, 2005). Those defined as abstinent reported no alcohol use; heavy drinkers reported 
≥14 drinks per week for men ≤66 years of age, or ≥ 7 drinks per week for women of any age 
and men > 66 years of age; those who reported any alcohol use but not “hazardous” as above 
were defined as moderate. Due to the low number of patients reporting hazardous drinking, 
the majority of analyses combined moderate and hazardous drinkers.
Baseline characteristics between those excluded as lost to follow-up and the final study 
population were examined using either t-tests for continuous or Chi-square tests for 
categorical variables. Baseline differences based on alcohol use were also evaluated using t-
tests or Chi-square tests. CD4 count at 12 months was compared based on alcohol 
consumption using univariate t-tests and multivariable linear regression. All demographic 
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and baseline clinical variables were used in subsequent regression models, except for highly 
correlated variables. Past experience with these data has shown that our socioeconomic 
variables – education level, income, and living in slum conditions – are highly correlated 
(colli-near) and that data on education are more complete and accurate; therefore, only 
education level was used in the regression models as an indicator of socioeconomic status.
This study was approved by the Ethical Review Committee of Kenyatta National Hospital 
(Nairobi, Kenya), the Institutional Review Board of the University of Washington (Seattle, 
WA, USA), and the US Centers for Disease Control and Prevention Associate Director for 
Science.
Results
Between January 2009 and December 2012, 4758 patients enrolled at the Hope Center 
(Figure 1). Of these, 3661 patients were excluded from the analysis due to the following: 
never on ART (n = 2034), ART-experienced at baseline (n = 968), or initiated ART > 3 
months after enrollment (n = 659). Of the remaining 1097 participants, two were not asked 
about their alcohol use during their baseline interview and 241 were either lost to follow-up 
during the 12-month study period (n = 184) or did not have a CD4 count at 12 months (n = 
57). Thus, the final analysis included 854 ART-naïve patients initiating ART within 3 
months of enrollment and followed for 12 months post-ART initiation. Sensitivity analysis 
did not reveal any significant difference in alcohol consumption between those who were 
retained 12 months post-ART versus those who were lost to follow up [data not shown].
Of the 854 HIV-infected patients that formed our Kenyan study population, 719 (84.2%) 
reported no alcohol consumption, 120 (14.1%) reported moderate alcohol use, and 15 
(1.8%) were classified as hazardous drinkers (Figure 1). More than half (61.1%) of the 
cohort were women, 630 (73.8%) had completed secondary education or higher, and 477 
(55.9%) were married or cohabitating (Table 1). A substantial number of participants 
(37.0%) reported monthly household income of less than or equal to $23 (USD) compared to 
the average monthly income of $113 (USD) (World Bank, 2016). Compared to men, women 
reported greater abstinence (90.4% vs. 74.4%; p < 0.001) and lower hazardous drinking 
(1.3% vs. 2.4%; p < 0.001) (see Figure 1).
Patients with post-primary education and household income above the poverty line were 
significantly more likely to consume alcohol compared to patients with lower education and 
household income below the poverty line (p = 0.045 and p < 0.001, respectively) (Table 1). 
That is, those with lower socioeconomic status were more likely to report abstinence. 
Although not statistically significant, there was a slight trend for higher baseline BMI and a 
marginally significant trend toward higher CD4 counts among drinkers versus abstainers.
Post-ART CD4 count increased among both drinkers and abstainers, with drinkers showing 
consistently higher median CD4 counts throughout the 12-month follow-up period (Table 2) 
though the difference was only significant at 6 months. BMI also increased steadily post-
ART and was slightly higher for drinkers than abstainers but not significantly. Treatment 
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interruption, as measured by the median number of late visits, did not differ between 
drinkers and abstainers during the 12-month period (p = 0.845).
Results of the multivariable regression models are shown in Table 3. CD4 count increase 
was associated with younger age (p = 0.003), higher baseline CD4 counts (p < 0.001), and 
alcohol use (p = 0.051). Using categorical variables for Moderate and Hazardous alcohol 
consumption separately does not change the basic structure of the model although in these 
models neither Moderate (p = 0.122) nor Hazardous (p = 0.093) consumption reach 
statistical significance.
Discussion
Our results indicate that within a population of HIV-infected clients initiating ART at an 
urban SSA clinic, more than 15% consume alcohol with less than 2% reporting hazardous 
alcohol use. We also found differences in reported alcohol use between genders with women 
reporting higher rates of abstinence (90.4% vs. 74.4%) and lower rates of hazardous 
drinking (1.3% vs. 2.4%). Alcohol use was also associated with higher socio-economic 
indicators. Regression models show that any alcohol use is associated with increased CD4 
counts, but neither Moderate nor Hazardous are by themselves significantly associated with 
increased CD4 counts.
The prevalence of alcohol consumption in our population of HIV-infected adults was similar 
to an estimate from Kenya of 14.6% among the adult population (WHO, 2011). However, 
other estimates of alcohol use are considerably higher in some subpopulations and regions in 
Kenya (e.g., Abu-Sáad & Mburu, 2001; Hargreaves et al., 2002; Ndetei et al., 2009; Shaffer 
et al., 2004).
Our results are in contrast to several earlier studies that found a negative or no impact of 
alcohol use on CD4 counts in that we found a positive association between alcohol 
consumption and post-ART CD4 counts even after controlling for other sociodemographic 
factors including overall health and treatment interruption. Our outcome is, however, similar 
to that from an earlier French study that found that those with low alcohol consumption (<10 
g daily) were more likely to have significantly higher CD4 cell counts over time compared 
to abstainers (Carrieri et al., 2014). That study also found that those who consumed more 
than 10 g daily had CD4 counts not significantly different from abstainers. Carrieri et al. 
(2014) suggest that low alcohol consumption may be acting as a proxy for other healthy 
behaviors, such as higher-quality food consumption, exercise, and perhaps higher social 
status rather than as a true “protective effect” much like alcohol's apparent risk-reductive 
effect on cardiovascular morbidity and mortality.
While we obtained similar results to the French study, it is difficult to assess the 
comparability between a developed European population and that in a resource-limited 
African context. Education/socioeconomic status among drinkers in our study was 
significantly higher at baseline suggesting that consuming alcohol may be an indicator of 
better nutrition, better overall health status, or higher socioeconomic status. Indeed, a cross-
sectional population-based study of alcohol and nutrition in South Africa (Serfontein, 
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Venter, Kruger, MacIntyre, & Pisa, 2010) found that increased alcohol use in urban contexts 
increased total dietary energy without a significant diminution of most macro- and 
micronutrients. Serfontein et al. (2010) suggest that those who can afford to buy alcohol may 
also have access to abundant and more nutritious foods. Our data suggest that, since there 
were no differences in treatment interruption, alcohol consumption is likely a confounding 
factor signaling higher socioeconomic status and/or access to more and better food much 
like the French study.
Kenyans also have a different mix of alcoholic beverages available to them, specifically 
“unrecorded” beverages, those alcoholic products – typically non-commercially produced 
beverages, such as the maize-based beer busaa and the distilled changaa – that are not 
counted in official estimates of drinking rates and may not be considered as alcohol 
consumption by some patients (Parry et al., 2005). In Kenya, these homebrews have been 
estimated to be consumed at almost three times the rate (by volume) of recorded beverages 
(Willis, 2002). Since these products tend to vary widely in ingredients, alcohol content, and 
standard serving size (Papas et al., 2010), the kind and degree to which these unrecorded 
products are consumed by our sample population represent a largely unknown confounding 
factor.
This study has several limitations. First, questions pertaining to alcohol use were asked only 
at baseline, so there are no data on alcohol use over time and whether being on ART affected 
consumption of alcohol. Second, only two basic questions were asked concerning alcohol 
use, rather than the more detailed Alcohol Use Disorders Identification Test (AUDIT) 
questionnaire which limited our analyses in that we could not adequately differentiate 
moderate alcohol use from alcohol abuse and dependence. Third, although our rates of 
alcohol consumption accord well with WHO survey data, they are much lower than that 
reported by other researchers in SSA generally and Kenya specifically. Finally, our data do 
not include information on the types of unrecorded beverages (busaa and changaa) that are 
likely consumed by some of our study population, nor do the social workers clarify with 
patients what quantity of alcohol constitutes “a drink”.
Nevertheless, this study adds important data to the debate regarding the effects of alcohol 
consumption on HIV-infected patients in SSA. Additional data are needed on the extent of 
alcohol consumption, alcohol use over time, and the types of alcohol being consumed and in 
what relative quantities such that effective, culturally appropriate interventions can be 
developed.
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Figure 1. 
Study flow chart.
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Table 1
Baseline characteristics of adults initiating ART, by alcohol use at enrollment.
Baseline characteristic
Abstinent Moderate and hazardous alcohol use
p-ValueN (%) or median (IQR) N (%) or median (IQR)
719 (84.2%) 135 (15.8%)
Age 37.2 (32.5–44.3) 37.9 (33.0–43.8) 0.605
Gender <0.001
 Male 247 (74.4%) 85 (25.6%)
 Female 472 (90.4%) 50 (9.6%)
Education 0.045
 Primary or lower 198 (88.4%) 26 (11.6%)
 Secondary or higher 521 (82.7%) 109 (17.3%)
Marital status 0.763
 Alone (Divorced/Separated/Single) 319 (84.6%) 58 (15.4%)
 Married/Cohabiting 400 (83.9%) 77 (16.1%)
WHO stage 0.024
 1/2 382 (81.6%) 86 (18.4%)
 3/4 337 (87.3%) 49 (12.7%)
BMI 21.8 (19.4–25.4) 22.6 (19.9–25.5) 0.132
CD4 126.0 (49.8–220.0) 151.0 (70.0–219.0) 0.099
Monthly household earnings <0.001
 >22.12 (USD) 340 (78.5%) 93 (21.5%)
 ≤22.12 (USD) (Poverty level) 289 (91.5%) 27 (8.5%)
Living in slum conditions 0.383
 No 437 (85.5%) 74 (14.5%)
 Yes 139 (82.7%) 29 (17.3%)
Note: p-values in bold text are significant at the 0.05 level.
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Table 2
CD4, BMI, and treatment interruption of adults initiating ART, by alcohol use at enrollment.
Time post-ART initiation
Abstinent (719) Mod + Hazard (135)
p-ValueMedian CD4 cells/uL (IQR) Median CD4 cells/uL (IQR)
Baseline 126.0 (49.8–220.0) 151.0 (70.0–219.0) 0.605
6 months 222.0 (145.0–348.0) 270.0 (166.0–369.5) 0.034
12 months 257.0 (171.2–385.0) 299.0 (190.5–432.0) 0.086
BMI BMI p-Value
Baseline 21.8 (19.4–25.4) 22.6 (19.9–25.5) 0.132
6 months 22.5 (20.3–25.5) 22.8 (20.6–26.0) 0.370
12 months 23.6 (21.0–26.6) 23.8 (21.2–26.3) 0.798
# Late visits # Late visits
12 months 5.0 (3.0–7.0) 5.0 (3.0–7.0) 0.845
Note: p-values in bold text are significant at the 0.05 level.
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Table 3
Multivariable regression models of CD4 at 12 months.
Alcohol use Estimatea 95% CI p
 Abstinent Reference NA NA
 Moderate/hazardous 33.24 (−0.1, 66.6) 0.051
Age (years) −2.14 (−3.5, −0.7) 0.003
Gender
 Male Reference NA NA
 Female 8.58 (−19.8, 36.9) 0.552
Education level
 None/primary Reference NA NA
 Secondary+ 17.07 (−10.0, 44.2) 0.216
Residence status
 Aloneb Reference NA NA
 Married/cohabitating 11.21 (−14.1, 36.6) 0.386
WHO stage
 1/2 Reference NA NA
 3/4 −8.77 (−34.8, 17.3) 0.509
Baseline BMI 1.09 (−1.8, 4.1) 0.723
Baseline CD4 0.59 (0.5, 0.7) <0.001
# Late pharmacy visits −1.46 (−5.4, 2.5) 0.471
Note: p-values in bold text are significant at the 0.05 level.
a
Estimate reflects CD4 count compared with referent.
b
Divorced/widowed/separated/single.
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